Results of trials assessing transarterial chemoembolization for treating hepatocellular carcinoma are critically underre
- PDF / 340,731 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 66 Downloads / 165 Views
INTERVENTIONAL
Results of trials assessing transarterial chemoembolization for treating hepatocellular carcinoma are critically underreported Jules Grégory 1,2,3 & Perrine Créquit 1,4 & Valérie Vilgrain 2,3,5 & Maxime Ronot 2,3,5 & Isabelle Boutron 1,2 Received: 5 February 2020 / Revised: 13 March 2020 / Accepted: 16 April 2020 # European Society of Radiology 2020
Abstract Objective We aimed to evaluate to what extent the results of registered randomized controlled trials (RCTs) assessing transarterial chemoembolization (TACE) for treating hepatocellular carcinoma (HCC) are publicly available. Methods We searched the Cochrane Central Register of Controlled Trials, the International Clinical Trials Registry Platform, and primary registries for RCTs assessing TACE for treating HCC, registered between January 2008 and August 2018, that had exceeded their completion date by more than 1 year. We systematically searched PubMed, EMBASE, and Google Scholar for a publication as well as the registry for results. The main outcomes were the availability of results, and the time to the first availability of results (i.e., posted on the registry or published). Secondary outcomes were the proportion of results available at 12 and 36 months after completion. Results Among 67 identified RCTs, including a total target number to 11,599 participants, 26 had publicly available results (39%; i.e., 42% of total target number of participants). Results of 25 RCTs (37%) were published, with only 3 having results posted on the registry and 2 with both published and posted results. The median (Q1–Q3) time from completion to the first public availability of results was 18 months (11–29). The cumulative percentages of RCTs with results available were 10% (95% CI, 3–17%) and 29% (95% CI, 17–39%) at 12 and 36 months, respectively, after completion. Conclusions Despite the ethical commitments and societal expectations for disclosure of results, the availability of results of RCTs on TACE for treating HCC is very limited. Key Points • Underreporting of trial results is a major cause of wasted medical research since inaccessible research results fail to help both patients and clinicians. • Transarterial chemoembolization (TACE) is the most common treatment for hepatocellular carcinoma (HCC) and has called for considerable research efforts. • Yet, almost two-thirds of randomized controlled trials assessing TACE for treating HCC did not yield any public results, either on the registry platform or in scientific journals. Keywords Publication bias . Therapeutic embolization . Hepatocellular carcinoma . Randomized controlled trial
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00330-020-06900-y) contains supplementary material, which is available to authorized users. * Jules Grégory [email protected]
2
Université de Paris, Paris, France
3
Department of Radiology, Paris Nord Val de Seine Hospitals, APHP, Beaujon Hospital, Clichy, France
1
4
Direction of Clinical Research, Foch Hospital, Suresne
Data Loading...
